Suppr超能文献

克罗恩病肛门瘘患者使用肛瘘塞的系统评价

The anal fistula plug in Crohn's disease patients with fistula-in-ano: a systematic review.

作者信息

Nasseri Y, Cassella L, Berns M, Zaghiyan K, Cohen J

机构信息

The Surgery Group of Los Angeles, Los Angeles, California, USA.

Division of Colon and Rectal Surgery, Cedars-Sinai Medical Center, Los Angeles, California, USA.

出版信息

Colorectal Dis. 2016 Apr;18(4):351-6. doi: 10.1111/codi.13268.

Abstract

AIM

This study aimed to review, consolidate and analyse the findings of studies investigating the efficacy of anal fistula plugs (AFPs) in treating fistula-in-ano in patients with Crohn's disease.

METHOD

A literature review was conducted via Pubmed, Embase, Medline, Scopus and the Cochrane Library for the period 1995-2015. Articles were selected and reviewed based on specific inclusion and exclusion criteria.

RESULTS

A total of 16 studies were extracted, of which 12 were included in the systematic review. In total, 84 patients (n = 1-20 per study) with a median age of 45 (18-72) years and a median follow-up time of 9 (3-24) months were analysed. The total success rate, defined as closure of the fistula tract, was 49/84 (58.3%, 95% CI 47-69). Success in patients with recurrent anal fistulae was 2/5 (40%, 95% CI 5-85). Overall, the success rates of Surgisis and GORE BIO-A brand plugs were 48/80 (60%, 95% CI 48-71) and 1/4 (25%, 95% CI 1-81). The recurrence rate of fistula-in-ano in the five studies that reported recurrence was 3/22 (13.6%). In two comparative studies, inferior overall success rates were found in patients who received preoperative immunomodulators vs. those who did not [3/11 (27.3%) vs. 17/23 (73.9%)].

CONCLUSION

The studies suggest that the use of an AFP in patients with Crohn's disease is a safe procedure with reasonable success, little morbidity and a low risk of incontinence. The current literature is limited by a number of factors, including small study cohorts, grouping of fistulae in Crohn's disease with other types of anal fistula, short and highly variable follow-up times and multiple confounding factors such as number of fistula tracts, use of preoperative steroids or immunosuppressants, previous use of setons and variation in surgical technique.

摘要

目的

本研究旨在回顾、整合并分析有关肛瘘塞(AFP)治疗克罗恩病患者肛瘘疗效的研究结果。

方法

通过PubMed、Embase、Medline、Scopus和Cochrane图书馆对1995年至2015年期间的文献进行综述。根据特定的纳入和排除标准选择并审查文章。

结果

共提取了16项研究,其中12项纳入系统评价。总共分析了84例患者(每项研究1 - 20例),中位年龄45岁(18 - 72岁),中位随访时间9个月(3 - 24个月)。定义为瘘管闭合的总成功率为49/84(58.3%,95%可信区间47 - 69)。复发性肛瘘患者的成功率为2/5(40%,95%可信区间5 - 85)。总体而言,Surgisis和GORE BIO - A品牌塞的成功率分别为48/80(60%,95%可信区间48 - 71)和1/4(25%,95%可信区间1 - 81)。在报告复发情况的五项研究中,肛瘘的复发率为3/22(13.6%)。在两项比较研究中,接受术前免疫调节剂治疗的患者总体成功率低于未接受者[3/11(27.3%)对17/23(73.9%)]。

结论

研究表明,在克罗恩病患者中使用AFP是一种安全的手术方法,成功率合理,发病率低,失禁风险低。目前的文献受到多种因素的限制,包括研究队列小、将克罗恩病肛瘘与其他类型肛瘘分组、随访时间短且高度可变以及多个混杂因素,如瘘管数量、术前使用类固醇或免疫抑制剂、既往使用挂线以及手术技术差异。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验